AU2016212777B2 - Single domain antibodies targeting CD1d - Google Patents

Single domain antibodies targeting CD1d Download PDF

Info

Publication number
AU2016212777B2
AU2016212777B2 AU2016212777A AU2016212777A AU2016212777B2 AU 2016212777 B2 AU2016212777 B2 AU 2016212777B2 AU 2016212777 A AU2016212777 A AU 2016212777A AU 2016212777 A AU2016212777 A AU 2016212777A AU 2016212777 B2 AU2016212777 B2 AU 2016212777B2
Authority
AU
Australia
Prior art keywords
ser
gly
compound
cd1d
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU2016212777A
Other languages
English (en)
Other versions
AU2016212777A1 (en
Inventor
Renee Cornelia Gerarda De Bruin
Tanja Denise DE GRUIJL
Roland LAMERIS
Johannes Jelle VAN DER VLIET
Hendrik Marinus Willem VERHEUL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lava Therapeutics NV
Original Assignee
Lava Therapeutics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics NV filed Critical Lava Therapeutics NV
Publication of AU2016212777A1 publication Critical patent/AU2016212777A1/en
Application granted granted Critical
Publication of AU2016212777B2 publication Critical patent/AU2016212777B2/en
Priority to AU2022200922A priority Critical patent/AU2022200922A1/en
Assigned to LAVA Therapeutics N.V. reassignment LAVA Therapeutics N.V. Amend patent request/document other than specification (104) Assignors: Lava Therapeutics B.V.
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
AU2016212777A 2015-01-27 2016-01-27 Single domain antibodies targeting CD1d Revoked AU2016212777B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200922A AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2014192 2015-01-27
NL2014192 2015-01-27
PCT/NL2016/050064 WO2016122320A1 (en) 2015-01-27 2016-01-27 Single domain antibodies targeting cd1d

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200922A Division AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Publications (2)

Publication Number Publication Date
AU2016212777A1 AU2016212777A1 (en) 2017-08-17
AU2016212777B2 true AU2016212777B2 (en) 2021-11-18

Family

ID=52630466

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016212777A Revoked AU2016212777B2 (en) 2015-01-27 2016-01-27 Single domain antibodies targeting CD1d
AU2022200922A Withdrawn AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200922A Withdrawn AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Country Status (11)

Country Link
US (4) US10501541B2 (https=)
EP (1) EP3250608B1 (https=)
JP (2) JP6743051B2 (https=)
KR (2) KR102574729B1 (https=)
CN (2) CN114504645A (https=)
AU (2) AU2016212777B2 (https=)
CA (1) CA2975078A1 (https=)
EA (1) EA201791691A1 (https=)
MX (1) MX386714B (https=)
SG (1) SG11201706128PA (https=)
WO (1) WO2016122320A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
AU2019344300A1 (en) * 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
WO2020113063A1 (en) * 2018-11-30 2020-06-04 Aleta Biotherapeutics Inc. Single domain antibodies against cll-1
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタｔ細胞活性化抗体の使用
CN116239687B (zh) * 2021-12-22 2026-03-24 北京世纪沃德生物科技有限公司 一种crp驼源单域抗体及其制备方法和应用
EP4285926A1 (en) * 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2024256586A1 (en) 2023-06-14 2024-12-19 LAVA Therapeutics N.V. Cd1d antibodies and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053021A1 (en) * 2011-10-14 2013-04-18 Cephalon Australia Pty Ltd ANTIBODIES TO CD1d

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
EP0751780B1 (en) 1993-06-21 2003-09-03 Brigham And Women's Hospital Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
WO2001022816A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
AU2001259230A1 (en) 2000-04-28 2001-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions
JP5184732B2 (ja) 2000-06-19 2013-04-17 ベス イスラエル デアコネス メディカル センター Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
EP1372668B1 (en) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US8084020B2 (en) * 2002-05-01 2011-12-27 Beth Israel Deaconess Medical Center Use of anti-CD1 antibodies for the modulation of immune responses
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
WO2005046711A2 (en) 2003-11-07 2005-05-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
DE602005022728D1 (de) 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
WO2006060117A2 (en) 2004-11-02 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
US8338173B2 (en) 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
JP5672647B2 (ja) * 2006-02-22 2015-02-18 独立行政法人理化学研究所 ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
EP1878440A1 (en) 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
US8012484B2 (en) 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
WO2010130830A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
US9670275B2 (en) 2012-01-23 2017-06-06 Ablynx N.V. Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN104334741B (zh) 2012-03-28 2018-08-17 歌德塔有限公司 组合的γ9δ2T细胞受体链交换
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US20170029454A1 (en) 2013-06-28 2017-02-02 The Scripps Research Institute Nkt cell ligands and methods of use
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
DK3129404T3 (da) 2014-04-10 2026-04-20 Lava Therapeutics N V Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
CA2988504A1 (en) 2014-07-02 2016-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
CN104829730A (zh) 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CN109195992A (zh) 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用
US20180028566A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
WO2019195535A1 (en) 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3927431A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
MA55903A (fr) 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
AU2021225870A1 (en) 2020-02-27 2022-10-20 Janssen Biotech, Inc. Materials and methods for modulating an immune response
IL296358A (en) 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
EP4237003A4 (en) 2020-10-28 2025-07-09 Janssen Biotech Inc COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053021A1 (en) * 2011-10-14 2013-04-18 Cephalon Australia Pty Ltd ANTIBODIES TO CD1d

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BROWN, M. et al., "Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2", The Journal of Immunology. 1996, Vol. 156, No. 9, pages 3285-3291 *
RUDIKOFF, S. et al., "Single amino acid substitution altering antigen-binding specificity", PNAS. 1982, Vol. 79, pages 1979-1983 *
SIONTOROU, C.G. et al., "Nanobodies as novel agents for disease diagnosis and therapy", International Journal of Nanomedicine, 2013. Vol. 8, pages 4215-4227 *
WINKLER, K. et al., "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody", The Journal of Immunology. 2000, Vol. 165, No. 8, pages 4505-4514 *

Also Published As

Publication number Publication date
JP7165701B2 (ja) 2022-11-04
KR20170128254A (ko) 2017-11-22
CA2975078A1 (en) 2016-08-04
JP6743051B2 (ja) 2020-08-19
JP2018508229A (ja) 2018-03-29
US20240425592A1 (en) 2024-12-26
CN107531787B (zh) 2022-01-18
WO2016122320A1 (en) 2016-08-04
CN114504645A (zh) 2022-05-17
AU2022200922A1 (en) 2022-03-03
US10501541B2 (en) 2019-12-10
SG11201706128PA (en) 2017-08-30
EP3250608A1 (en) 2017-12-06
US20200115450A1 (en) 2020-04-16
HK1247937A1 (en) 2018-10-05
US20240067726A1 (en) 2024-02-29
US11591394B2 (en) 2023-02-28
MX2017009680A (es) 2018-04-13
CN107531787A (zh) 2018-01-02
US12110328B2 (en) 2024-10-08
MX386714B (es) 2025-03-11
KR20230132604A (ko) 2023-09-15
AU2016212777A1 (en) 2017-08-17
KR102574729B1 (ko) 2023-09-04
JP2020172550A (ja) 2020-10-22
EP3250608B1 (en) 2024-08-21
US20180142020A1 (en) 2018-05-24
EA201791691A1 (ru) 2018-01-31

Similar Documents

Publication Publication Date Title
US12110328B2 (en) Single domain antibodies targeting CD1d
US20250026840A1 (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
EP3858856A1 (en) Anti-b7-h3 monoclonal antibody and use thereof in cell therapy
EP3708582A1 (en) 4-1bb antibody and preparation method and use thereof
TW202546009A (zh) 抗hk2嵌合抗原受體(car)
CN116731169B (zh) 一种分拣蛋白1特异性的纳米抗体及其应用
TWI800824B (zh) 一種抗cd19抗體的抗體及其製備和應用
CN118103071A (zh) Herv-k抗体治疗剂
EP4397685A1 (en) Anti-cd3 humanized antibody
EP4506368A1 (en) Bispecific antibody to human tim-3 and human cd39, and applications thereof
US20250333515A1 (en) Binding agents and methods of use thereof
WO2023001155A1 (zh) 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
CN108610422A (zh) 抑制pd-1/pd-l1信号通路的结合分子
JP2024517985A (ja) 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー
HK1247937B (en) Single domain antibodies targeting cd1d
EA042112B1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
CN118488961A (zh) Herv-k抗体、细胞、疫苗及药物治疗剂
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
WO2023177821A2 (en) Binding domains and methods of use thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: LAVA THERAPEUTICS N.V.

Free format text: FORMER NAME(S): LAVA THERAPEUTICS B.V.

FGA Letters patent sealed or granted (standard patent)
MAK Offer to surrender letters patent
MAL Surrender and revocation of letters patent

Effective date: 20250116